Cell Source, Inc. Stock

CLCS

US15114L1044

Biotechnology & Medical Research

Real-time OTC Markets 12:26:06 03/06/26 am AEST			5-day change	1st Jan Change
0.8200 ^USD	+2.50%		+95.47%	+64.00%

15/05	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
07/04	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Latest news: Cell Source, Inc.

15/05	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
07/04	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/04	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/01	Cell Source, Inc. announced that it has received $1.5 million in funding	CI
22/11/24	Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer Center	CI
15/11/24	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
20/08/24	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
30/07/24	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/06/24	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24/06/24	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/03/24	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
10/11/23	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
20/09/23	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

More news

Press Releases: Cell Source, Inc.

21/05	Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week	AQ
15/05	Cell Source, Inc. to Present at the LD Micro Invitational XVI	NE
15/05	Cell Source : Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)	PU
07/04	Cell Source : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
09/12/22	Note 2 - Going Concern and Management Plans	AQ

More press releases

Managers and Directors: Cell Source, Inc.

Manager	Title	Age	Since
Itamar Shimrat CEO	Chief Executive Officer	66	30/06/2014

Director	Title	Age	Since
Dennis Brown CHM	Chairman	77	18/05/2015
Darlene Soave BRD	Director/Board Member	82	25/03/2021
George Verstraete BRD	Director/Board Member	72	10/03/2022

More insiders

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	USD 0.4000	-14.88%	4,575
01/10/26	USD 0.4699	+14.61%	750
30/09/26	USD 0.4100	+2.50%	7,310
29/09/26	USD 0.4000	-8.53%	11,600
28/09/26	USD 0.4373	+4.25%	575

Real-time OTC Markets

More quotes

Market Cap	24.41M 21.78M 20.29M 18.46M 34.77M 2.35B 35.03M 245M 95.38M 1.2B 91.64M 89.66M 3.86B	P/E 2023	-2.65x	P/E 2024	-2.49x
Enterprise Value	34.92M 31.15M 29.02M 26.41M 49.74M 3.36B 50.1M 351M 136M 1.72B 131M 128M 5.52B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	80.32%	Yield 2023 *	-	Yield 2024	-

1 day	+2.50%
1 week	+95.47%
Current month	+100.00%
1 month	+58.58%
3 months	-11.83%
6 months	+2.50%
Current year	+64.00%

1 week	0.36	0.82
1 month	0.36	0.82
Current year	0.25	2.25
1 year	0.25	2.25
3 years	0	2.25
5 years	0	2.25
10 years	0	2.55

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/8/21	Darlene Soave	Others	Director	800,000	2.4492%
30/6/21	David Zolty	Others	Director	4,860	0.0149%
30/6/21	Dennis Brown	Others	Chairman	2,976	0.0091%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELL SOURCE, INC.	+2.50%	+95.47%	+134.29%	+22.39%	27.54M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.81%	+19.51%	+78.12%	57.39B
LONZA GROUP AG	+1.63%	-1.61%	+3.16%	+36.89%	47.64B
REVOLUTION MEDICINES, INC.	-0.15%	+1.99%	+341.71%	+714.53%	44.29B
IQVIA HOLDINGS INC.	+1.91%	-2.94%	+28.28%	+32.95%	42.5B
BEONE MEDICINES AG	+0.52%	-1.92%	+4.48%	+110.92%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.36%	-1.92%	-7.59%	-11.53%	24.34B
Average	+1.14%	-0.53%	+61.39%	+115.94%	39.06B
Weighted average by Cap.	+1.25%	-0.84%	+57.49%	+135.57%

Cell Source, Inc. Stock

Stocks

CLCS

US15114L1044

Biotechnology & Medical Research

Valuation: Cell Source, Inc.

Chart: Cell Source, Inc.

Latest news: Cell Source, Inc.

Press Releases: Cell Source, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cell Source, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

	2023	2024
Net sales	-	-
Net income	-5.32M -4.75M -4.42M -4.02M -7.58M -512M -7.64M -53.44M -20.79M -262M -19.98M -19.54M -841M	-4.51M -4.03M -3.75M -3.41M -6.43M -435M -6.48M -45.32M -17.63M -222M -16.94M -16.57M -713M
Net Debt	9.27M 8.27M 7.71M 7.01M 13.21M 893M 13.31M 93.14M 36.24M 456M 34.81M 34.06M 1.47B	10.51M 9.37M 8.73M 7.95M 14.97M 1.01B 15.08M 106M 41.06M 517M 39.45M 38.6M 1.66B